StreetInsider.com News Articles

InterVenn Biosciences adds Ford and Levine to board

Mon, 18 May 2026 09:02:16 -0400

InterVenn Biosciences announced the appointment of Alec Ford and Mitch Levine to its board of directors. The South San Francisco-based life sciences company focuses on glycoproteomics for healthcare solutions.

Ford brings over 30 years of experience in genomics, pharmaceutical and biotechnology industries. He currently serves as chief executive officer of Karius, a liquid biopsy company for infectious diseases. Ford previously held the chief operating officer position at Myriad Genetics, where he launched products and scaled business units in women's health, oncology, urology and prenatal screening. His career includes leadership roles at Novartis, Sanofi-Aventis, Nektar Therapeutics and Pfizer.

Levine has extensive experience in

InterVenn Biosciences adds Ford and Levine to board

Mon, 18 May 2026 09:02:16 -0400

Levine has extensive experience in

InterVenn Biosciences adds Ford and Levine to board

Mon, 18 May 2026 09:02:16 -0400

Levine has extensive experience in

InterVenn Biosciences adds Ford and Levine to board

Mon, 18 May 2026 09:02:16 -0400

Levine has extensive experience in

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

SOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ -- InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

Mon, 18 May 2026 09:02:00 -0400

"We are excited to welcome Alec and Mitch to InterVenn's Board of

iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Mon, 23 Jun 2025 16:06:16 -0400

Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-to-head comparison with another commercially available test kit.

The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.

This positive data supports iMDx’s top priority of launching its first clinical molecular diagnostic test kit and capturing value in the estimated $1 billion transplant rejection testing market. In 2025 to date, iMDx is executing the key steps typically necessary to transition from product development

iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Mon, 23 Jun 2025 16:06:16 -0400

The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.

iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Mon, 23 Jun 2025 16:06:16 -0400

The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.

iMDx (IMDX) Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Mon, 23 Jun 2025 16:06:16 -0400

The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing